AVRO

AVROBIO, Inc. [AVRO] Stock Forecast

Q: What is AVROBIO, Inc. stock symbol ?

AVROBIO, Inc. is a US stock, located in Cambridge of Ma and trading under the symbol AVRO

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

AVRO Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

AVRO has more than 16 years of cash runway (200 months)

Top 10 Correlated ETFs

AVRO

Top 10 Correlated Stocks

AVRO

In the News

04:03 29 Sep 2023 AVRO

Avrobio: Net-Net Biotech Pursuing Strategic Alternatives

After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alternatives recently. The process could close its valuation gap soon. There is potential for significantly more value if Avrobio can also monetize its remaining candidates.

08:51 29 Sep 2023 AVRO

AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46%

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges 46% in response on Wednesday.

06:00 29 Sep 2023 AVRO

How to Handle Penny Stocks Volatility in 2023

Penny stocks continue to offer incredible opportunities for investors in 2023. As high-growth, micro-cap equities, they have the potential to outperform traditional stocks, particularly given their inherent affordability, which allows for a broader, more diversified portfolio.

11:43 29 Sep 2023 AVRO

Why Is AVROBIO (AVRO) Stock Up 83% Today?

AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has Novartis agreeing to pay $87.5 million in cash to AVROBIO for an investigational hematopoietic stem cell ( HSC ) gene therapy program.

04:33 29 Sep 2023 AVRO

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

12:21 29 Sep 2023 AVRO

AVROBIO Shares Jumps On Encouraging Data From Early-Stage Gene Therapy Study

AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition characterized by the accumulation of the amino acid cystine (a building block of proteins) within cells.

12:55 29 Sep 2023 AVRO

After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year after infusion. Get the Inside Access Traders Are Using to Profit More and Win Bigger.

09:12 29 Sep 2023 AVRO

Trading Penny Stocks? Top Stock Market News for February 9th, 2022

What you need to know about trading penny stocks today The post Trading Penny Stocks? Top Stock Market News for February 9th, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

11:30 29 Sep 2023 AVRO

Here's Why AVROBIO, Inc. (AVRO) is Poised for a Turnaround After Losing 19.7% in 4 Weeks

The heavy selling pressure might have exhausted for AVROBIO, Inc. (AVRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

07:00 29 Sep 2023 AVRO

AVROBIO to Present at Cowen's 2nd Annual Genetic Medicines Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced Azadeh Golipour, Ph.D., chief technology officer at AVROBIO, will present virtually at Cowen's 2nd Annual Genetic Medicines Summit at 2:00 p.m. ET on Thursday, Feb. 3, 2022. About AVROBIO Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throu

AVRO Financial details

Company Rating

Neutral

Market Cap

67.69M

Income

53.09M

Revenue

Book val./share

2.77

Cash/share

2.83

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

06 Nov 2023

P/E

1.28

Forward P/E

PEG

-0.09

P/S

P/B

0.56

P/C

0.54

P/FCF

-0.91

Quick Ratio

10.71

Current Ratio

11.05

Debt / Equity

0.02

LT Debt / Equity

EPS (TTM)

1.2

EPS next Y

EPS next Q

EPS this Y

-12%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-378.18%

SMA20

1.99%

SMA50

14.07%

SMA100

97.44%

Inst Own

45.46%

Inst Trans

0.88%

ROA

40%

ROE

61%

ROC

-0.04%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

44.53M

Shs Float

29.54M

Target Price

52W Range

0.56-1.93

52W High

52W Low

RSI

50.5

Rel Volume

0.12

Avg Volume

1.09M

Volume

125.15K

Perf Week

-1.91%

Perf Month

0.65%

Perf Quarter

58.76%

Perf Half Y

46.67%

Beta

1.56155

Volatility

0.01%, 0.04%

Prev Close

Price

1.54

Change

-0.65%

AVRO Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-3.45	-2.63	-3.27	-2.75	-2.42
Operating cash flow per share	-2.8	-2.47	-2.73	-2.29	-2.22
Free cash flow per share	-2.94	-2.52	-2.76	-2.34	-2.23
Cash per share	9.4	6.82	7.17	4.42	2.12
Book value per share	9.09	6.78	7.02	3.95	1.72
Tangible book value per share	9.09	6.78	7.02	3.95	1.72
Share holders equity per share	9.09	6.78	7.02	3.95	1.72
Interest debt per share	0	0	0	0.34	0.41
Market cap	223.7M	552.21M	504.71M	164.99M	31.05M
Enterprise value	97.4M	365.16M	245.03M	-9.63M	-44.05M
P/E ratio	-4.83	-7.66	-4.26	-1.4	-0.29
Price to sales ratio	0	0	0	0	0
POCF ratio	-5.94	-8.16	-5.11	-1.68	-0.32
PFCF ratio	-5.67	-7.97	-5.05	-1.64	-0.32
P/B Ratio	1.83	2.97	1.98	0.97	0.41
PTB ratio	1.83	2.97	1.98	0.97	0.41
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.11	-4.82	-2.04	0.08	0.42
EV to operating cash flow	-2.59	-5.4	-2.48	0.1	0.45
EV to free cash flow	-2.47	-5.27	-2.45	0.1	0.45
Earnings yield	-0.21	-0.13	-0.23	-0.71	-3.41
Free cash flow yield	-0.18	-0.13	-0.2	-0.61	-3.14
Debt to equity	0	0	0	0.09	0.23
Debt to assets	0	0	0	0.07	0.17
Net debt to EBITDA	2.73	2.47	2.16	1.47	0.71
Current ratio	12.26	13.96	16.09	10.27	8.23
Interest coverage	0	0	0	530.54	-352.62
Income quality	0.81	0.93	0.83	0.82	0.92
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.05	0.02	0.01	0.03	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-4.82	-1.86	-0.98	-1.76	-0.19
Stock based compensation to revenue	0	0	0	0	0
Graham number	26.57	20.03	22.75	15.63	9.7
ROIC	-0.38	-0.4	-0.47	-0.64	-1.12
Return on tangible assets	-0.35	-0.36	-0.44	-0.58	-1.02
Graham Net	8.59	6.31	6.72	3.64	1.46
Working capital	119.41M	181.68M	250.63M	179.76M	87.56M
Tangible asset value	122.18M	186.01M	254.34M	169.48M	75.37M
Net current asset value	118.73M	181.2M	250.35M	164.78M	71.1M
Invested capital	0	0	0	0.09	0.23
Average receivables	772.5K	1.84M	2.35M	2.63M	1.48M
Average payables	1.66M	3.37M	3.32M	3.08M	1.94M
Average inventory	-772.5K	-1.84M	-2.35M	-2.63M	-1.48M
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.38	-0.39	-0.47	-0.69	-1.41
Capex per share	-0.14	-0.06	-0.03	-0.06	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0	0	0	0	0
Net income per share	-0.65	-0.52	0.74	-0.55	1.53
Operating cash flow per share	-0.67	-0.38	-0.54	-0.46	-0.33
Free cash flow per share	-0.67	-0.38	-0.54	-0.46	-0.33
Cash per share	3.03	2.65	2.11	1.64	2.83
Book value per share	2.71	2.24	1.72	1.2	2.77
Tangible book value per share	2.71	2.24	1.72	1.2	2.77
Share holders equity per share	2.71	2.24	1.72	1.2	2.77
Interest debt per share	0.35	0.35	0.4	0.48	0.07
Market cap	40.2M	28.01M	31.09M	44.04M	41.93M
Enterprise value	-77.1M	-72.75M	-44.01M	-9.95M	-80.38M
P/E ratio	-0.35	-0.31	0.24	-0.46	0.16
Price to sales ratio	0	0	0	0	0
POCF ratio	-1.38	-1.71	-1.31	-2.17	-2.86
PFCF ratio	-1.37	-1.7	-1.31	-2.17	-2.86
P/B Ratio	0.34	0.29	0.41	0.83	0.34
PTB ratio	0.34	0.29	0.41	0.83	0.34
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	2.81	3.21	1.74	0.39	5.19
EV to operating cash flow	2.65	4.43	1.86	0.49	5.49
EV to free cash flow	2.64	4.41	1.85	0.49	5.49
Earnings yield	-0.7	-0.82	1.05	-0.55	1.61
Free cash flow yield	-0.73	-0.59	-0.77	-0.46	-0.35
Debt to equity	0.13	0.16	0.23	0.4	0.02
Debt to assets	0.1	0.12	0.17	0.25	0.02
Net debt to EBITDA	4.28	4.45	2.97	2.14	7.9
Current ratio	11.11	7.8	8.23	6.2	11.05
Interest coverage	-97.45	-207.07	-134.35	-101.69	137.39
Income quality	1.04	0.71	0.95	0.81	-0.22
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0.01	0.01	0	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.42	-0.24	-0.44	-0.02	0
Stock based compensation to revenue	0	0	0	0	0
Graham number	6.29	5.13	5.37	3.85	9.75
ROIC	-0.21	-0.2	0.35	-0.32	0.53
Return on tangible assets	-0.19	-0.18	0.31	-0.29	0.5
Graham Net	2.51	2.06	1.46	0.95	2.6
Working capital	129.3M	110.04M	87.56M	60.65M	117.18M
Tangible asset value	118.34M	98.09M	75.37M	53M	122.04M
Net current asset value	114.18M	94.83M	71.1M	42.32M	117.05M
Invested capital	0.13	0.16	0.23	0.4	0.02
Average receivables	2.9M	2.97M	1.63M	269.5K	270K
Average payables	2.03M	921K	1.1M	487.5K	831K
Average inventory	5.88M	6.34M	3.12M	-692K	988.5K
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.24	-0.23	0.43	-0.46	0.55
Capex per share	0	0	0	0	0

AVRO Frequently Asked Questions

What is AVROBIO, Inc. stock symbol ?

AVROBIO, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol AVRO

What is AVROBIO, Inc. stock quote today ?

AVROBIO, Inc. stock price is $1.54 today.

Is AVROBIO, Inc. stock public?

Yes, AVROBIO, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 1.09M
Market Capitalization 67.69M
Employee 78
CEO Mr. Erik John Ostrowski M.B.A.
Headquarters Cambridge,MA,US
IPO Date 2018-06-21
Website https://www.avrobio.com

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are collected from patients and modified with a lentiviral vector to insert functional copies of the gene that is defective in the target disease. The company's product includes AVR-RD-01, a gene therapy for the treatment of Fabry disease. It is also developing AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of type 1 Gaucher disease; AVR-RD-03, for the treatment of Pompe disease; AVR-RD-04 for the treatment of cystinosis; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-06 that is in preclinical stage for the treatment of Gaucher disease type 3. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.